Food and Drug Administration staff scientists opposed easing peptide restrictions, concluding that existing data lacks sufficient evidence to establish safety or efficacy for compounds like BPC-157.

From the articleTrump administration advances plan for peptide drugs favored by RFK Jr.Also in Trump administration advances plan for peptide drugs favored by RFK Jr., FDA advances peptide push to White House, RFK Jr.’s Agency Sends Plan for Peptide Drugs to White House